The Fgfr2 W290R mouse model of Crouzon syndrome

Child's Nervous System

Volumn 28, Issue 9, 2012, Pages 1495-1503

  Gong, S G ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Craniofacial development; Craniosynostosis; Fgfr2 IIIb and IIIc isoforms; Loss of function; Mouse model for human diseases

Indexed keywords

FIBROBLAST GROWTH FACTOR 10; FIBROBLAST GROWTH FACTOR RECEPTOR 2; TRANSCRIPTION FACTOR MSX2;

ARTICLE; CROUZON SYNDROME; DISEASE MODEL; GENE; GENE FUNCTION; GENE MUTATION; GENE SILENCING; GLYCOSYLATION; MISSENSE MUTATION; MOUSE MUTANT; MUTAGENESIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FOLDING; SIGNAL TRANSDUCTION; SKELETON MALFORMATION; W290R GENE;

ANIMALS; ARGININE; BONE AND BONES; CARTILAGE; CRANIAL SUTURES; CRANIOFACIAL DYSOSTOSIS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MUTATION; PHENOTYPE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; TRYPTOPHAN;

EID: 84866080278     PISSN: 02567040     EISSN: 14330350     Source Type: Journal    
DOI: 10.1007/s00381-012-1792-y     Document Type: Article

References (61)

1. Johnson D, Wilkie AOM (2011) Craniosynostosis. Eur J Hum Genet 19:369-376
2. Wilkie AOM, Bochukova EG, Hansen RMS, Taylor IB, Sahan VR-E et al (2007) Clinical dividends from the molecular genetic diagnosis of craniosynostosis. Am J Med Genet A 143A:1941-1949
3. Wilkie AOM (2005) Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations. Cytokine Growth Factor Rev 16:187-203
4. Jabs EW, Müller U, Li X, Ma L, Luo W et al (1993) A mutation in the homeodomain of the human MSX2 gene in a family affected with autosomal dominant craniosynostosis. Cell 75:443-450
5. Morriss-Kay GM, Wilkie AOM (2005) Growth of the normal skull vault and its alteration in craniosynostosis: insights from human genetics and experimental studies. J Anat 207:637-653
6. Wilkie AOM, Byren JC, Hurst JA, Jayamohan J, Johnson D et al (2010) Prevalence and complications of single-gene and chromosomal disorders in craniosynostosis. Pediatrics 126:e391-e400
7. Passos-Bueno MR, Wilcox WR, Jabs EW, Sertié AL, Alonso LG et al (1999) Clinical spectrum of fibroblast growth factor receptor mutations. Hum Mutat 14:115-125
8. Lajeunie E, Heuertz S, El Ghouzzi V, Martinovic J, Renier D et al. (2006) Mutation screening in patients with syndromic craniosynostoses indicates that a limited number of recurrent FGFR2 mutations accounts for severe forms of Pfeiffer syndrome. Eur J Hum Genet 14(3):289-298.
9. Hajihosseini MK (2008) Fibroblast growth factor signaling in ranial sutrue development and pathogenesis. In: Rice DP (ed) Frontiers in oral biologycraniofacial sutures: development, disease and treatment. Karger, Basel, pp 160-177
10. Ornitz DM, Marie PJ (2002) FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev 16:1446-1465
11. Thisse B, Thisse C (2005) Functions and regulations of fibroblast growth factor signaling during embryonic development. Dev Biol 287:390
12. Chaudhuri M, Moscatelli D, Basilico C (1993) Involvement of the conserved acidic amino acid domain of FGF receptor 1 in ligand-receptor interaction. J Cell Physiol 157:209-216
13. Eisemann A, Ahn J, Graziani G, Tronick S, Ron D (1991) Alternative splicing generates at least five different isoforms of the human basic-FGF receptor. Oncogene 6:1195-1202
14. Champion-Arnaud P, Ronsin C, Gilbert E, Gesnel M, Houssaint E et al (1991) Multiple mRNAs code for proteins related to the BEK fibroblast growth factor receptor. Oncogene 6:979-987
15. Chellaiah AT, McEwen DG, Werner S, Xu J, Ornitz DM (1994) Fibroblast growth factor receptor (FGFR) 3. Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF/FGF-1. J Biol Chem 269:11620-11627
16. Werner S, Duan DS, de Vries C, Peters KG, Johnson DE et al (1992) Differential splicing in the extracellular region of fibroblast growth factor receptor 1 generates receptor variants with different ligand-binding specificities. Mol Cell Biol 12:82-88
17. Orr-Urtreger A, Bedford MT, Burakova T, Arman E, Zimmer Y et al (1993) Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2). Dev Biol 158:475-486
18. Hanneken A (2001) Structural characterization of the circulating soluble FGF receptors reveals multiple isoforms generated by secretion and ectodomain shedding. FEBS Lett 489:176-181
19. Celli G, LaRochelle WJ, Mackem S, Sharp R, Merlino G (1998) Soluble dominant-negative receptor uncovers essential roles for fibroblast growth factors in multi-organ induction and patterning. EMBO J 17:1642-1655
20. Wheldon LM, Khodabukus N, Patey SJ, Smith TG, Heath JK et al (2011) Identification and characterization of an inhibitory fibroblast growth factor receptor 2 (FGFR2) molecule, up-regulated in an Apert syndrome mouse model. Biochem J 436:71-81
21. Lajeunie E, Heuertz S, El Ghouzzi V, Martinovic J, Renier D et al (2006) Mutation screening in patients with syndromic craniosynostoses indicates that a limited number of recurrent FGFR2 mutations accounts for severe forms of Pfeiffer syndrome. Eur J Hum Genet 14:289-298
22. Fo G, Cl Z (2011) From cradle to grave: the multiple roles of fibroblast growth factors in neural development. Neuron 71:574-588
23. Dorey K, Amaya E (2010) FGF signalling: diverse roles during early vertebrate embryogenesis. Development 137:3731-3742
24. Wesche J, Haglund K, Haugsten E (2011) Fibroblast growth factors and their receptors in cancer. Biochem J 437:199-213
25. Ciruna BG, Schwartz L, Harpal K, Yamaguchi TP, Rossant J (1997) Chimeric analysis of fibroblast growth factor receptor-1 (Fgfr1) function: a role for FGFR1 in morphogenetic movement through the primitive streak. Development 124:2829-2841
26. Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM (1996) Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat Genet 12:390-397
27. De Moerlooze L, Spencer-Dene B, Revest J, Hajihosseini M, Rosewell I et al (2000) An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis. Development 127:483-492
28. Deng CX, Wynshaw-Boris A, Shen MM, Daugherty C, Ornitz DM et al (1994) Murine FGFR-1 is required for early postimplantation growth and axial organization. Genes Dev 8:3045-3057
29. Mai S, Wei K, Flenniken A, Adamson SL, Rossant J et al (2010) The missense mutation W290R in Fgfr2 causes developmental defects from aberrant IIIb and IIIc signaling. Dev Dyn 239:1888-1900
30. Oldridge M, Wilkie AOM, Sianey SF, Poole MD, Pulleyn LJ et al (1995) Mutations in the third immunoglobulin domain of the fibroblast growth factor receptor-2 gene in Crouzon syndrome. Hum Mol Genet 4:1077-1082
31. Park W-J, Meyers GA, Li X, Theda C, Day D et al (1995) Novel FGFR2 mutations in Crouzon and Jackson-Weiss syndromes show allelic heterogeneity and phenotypic variability. Hum Mol Genet 4:1229-1233
32. Steinberger D, Mulliken JB, Müller U (1996) Crouzon syndrome: previously unrecognized deletion, duplication, and point mutation within FGFR2 gene. Hum Mutat 8:386-390
33. Tartaglia M, Valeri S, Velardi F, Rocco CD, Battaglia PA (1997) Trp290Cys mutation in exon IIIa of the fibroblast growth factor receptor 2 (FGFR2) gene is associated with Pfeiffer syndrome. Hum Genet 99:602-606
34. Wilkie AO (1997) Craniosynostosis: genes and mechanisms. Hum Mol Genet 6:1647-1656
35. Schaefer F, Anderson C, Can B, Say B (1998) Novel mutation in the FGFR2 gene at the same codon as the Crouzon syndrome mutations in a severe Pfeiffer syndrome type 2 case. Am J Med Genet 75:252-255
36. Eswarakumar VP, Horowitz MC, Locklin R, Morriss-Kay GM, Lonai P (2004) A gain-of-function mutation of Fgfr2c demonstrates the roles of this receptor variant in osteogenesis. Proc Natl Acad Sci U S A 101:12555-12560
37. Eswarakumar VP, Monsonego-Ornan E, Pines M, Antonopoulou I, Morriss-Kay GM et al (2002) The IIIc alternative of Fgfr2 is a positive regulator of bone formation. Development 129:3783-3793
38. Galvin BD, Hart KC, Meyer AN, Webster MK, Donoghue DJ (1996) Constitutive receptor activation by Crouzon syndrome mutations in fibroblast growth factor receptor (FGFR)2 and FGFR2/Neu chimeras. Proc Natl Acad Sci U S A 93:7894-7899
39. Mangasarian K, Li Y, Mansukhani A, Basilico C (1997) Mutation associated with Crouzon syndrome causes ligand-independent dimerization and activation of FGF receptor-2. J Cell Physiol 172:117-125
40. Wang Y, Xiao R, Yang F, Karim BO, Iacovelli AJ et al (2005) Abnormalities in cartilage and bone development in the Apert syndrome FGFR2+/S252W mouse. Development 132:3537-3548
41. Perlyn CA, DeLeon VB, Babbs C, Govier D, Burell L et al (2006) The craniofacial phenotype of the Crouzon mouse: analysis of a model for syndromic craniosynostosis using three-dimensional microCT. Cleft Palate Craniofac J 43:740-748
42. Hajihosseini MK, Wilson S, De Moerlooze L, Dickson C (2001) A splicing switch and gain-of-function mutation in FgfR2-IIIc hemizygotes causes Apert/Pfeiffer-syndrome-like phenotypes. Proc Natl Acad Sci U S A 98:3855-3860
43. Arman E, Haffner-Krausz R, Gorivodsky M, Lonai P (1999) Fgfr2 is required for limb outgrowth and lung-branching morphogenesis. Proc Natl Acad Sci U S A 96:11895-11899
44. Sekine K, Ohuchi H, Fujiwara M, Yamasaki M, Yoshizawa T et al (1999) Fgf10 is essential for limb and lung formation. Nat Genet 21:138-141
45. Steinberg Z, Myers C, Heim VM, Lathrop CA, Rebustini IT et al (2005) FGFR2b signaling regulates ex vivo submandibular gland epithelial cell proliferation and branching morphogenesis. Development 132:1223-1234
46. Zhang X, Stappenbeck TS, White AC, Lavine KJ, Gordon JI et al (2006) Reciprocal epithelial-mesenchymal FGF signaling is required for cecal development. Development 133:173-180
47. Spencer-Dene B, Sala FG, Bellusci S, Gschmeissner S, Stamp G et al (2006) Stomach development is dependent on fibroblast growth factor 10/fibroblast growth factor receptor 2b-mediated signaling. Gastroenterology 130:1233-1244
48. Katoh M, Katoh M (2006) FGF signaling network in the gastrointestinal tractreview. Int J Oncol 29:163-168
49. Hatch NE, Hudson M, Seto ML, Cunningham ML, Bothwell M (2006) Intracellular retention, degradation, and signaling of glycosylation-deficient FGFR2 and craniosynostosis syndrome-associated FGFR2C278F. J Biol Chem 281:27292-27305
50. Neilson KM, Friesel RE (1995) Constitutive activation of fibroblast growth factor receptor-2 by a point mutation associated with Crouzon syndrome. J Biol Chem 270:26037-26040
51. Shotelersuk V, Ittiwut C, Srivuthana S, Mahatumarat C, Lerdlum S et al (2002) Distinct craniofacial-skeletal-dermatological dysplasia in a patient with W290C mutation in FGFR2. Am J Med Genet 113:4-8
52. Meyers GA, Day D, Goldberg R, Daentl DL, Przylepa KA et al (1996) FGFR2 exon IIIa and IIIc mutations in Crouzon, Jackson-Weiss, and Pfeiffer syndromes: evidence for missense changes, insertions, and a deletion due to alternative RNA splicing. Am J Hum Genet 58:491-498
53. Cohen MJ (1993) Pfeiffer syndrome update, clinical subtypes, and guidelines for differential diagnosis. Am J Med Genet 45:300-307
54. Chen C, Lin S, Su Y, Chien S, Tsai F et al (2008) Craniosynostosis and congenital tracheal anomalies in an infant with Pfeiffer syndrome carrying the W290C FGFR2 mutation. Genet Couns 19:165-172
55. Oliveira NAJ, Alonso LG, Fanganiello RD, Passos-Bueno MR (2006) Further evidence of association between mutations in FGFR2 and syndromic craniosynostosis with sacrococcygeal eversion. Birth Defects Res A Clin Mol Teratol 76:629-633
56. Zarate YA, Putnam PE, Saal HM (2010) Intestinal malrotation in a patient with Pfeiffer syndrome type 2. Cleft Palate Craniofac J 47(6):638-641
57. Cohen MM, Kreiborg S (1993) Visceral anomalies in the Apert syndrome. Am J Med Genet 45:758-760
58. Miraoui H, Ringe J, Haupl T, Marie PJ (2010) Increased EFG- and PDGFalpha-receptor signaling by mutant FGF-receptor 2 contributes to osteoblast dysfunction in Apert craniosynostosis. Hum Mol Genet 19:1678-1689
59. Ahmed Z, Schuller AC, Suhling K, Tregidgo C, Ladbury JE (2008) Extracellular point mutations in FGFR2 elicit unexpected changes in intracellular signalling. Biochem J 413:37-49
60. Parodi A (2000) Role of N-oligosaccharide endoplasmic reticulum processing reactions in glycoprotein folding and degradation. Biochem J 348:1-13
61. Eswarakumar VP, Özcan F, Lew ED, Bae JH, Tomé F et al (2006) Attenuation of signaling pathways stimulated by pathologically activated FGF-receptor 2 mutants prevents craniosynostosis. Proc Natl Acad Sci U S A 103:18603-18608